Methods of treating or preventing rheumatic disease
The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom.
1. A method for treating a rheumatic disease in a subject, the method comprising systemically administering to the subject a therapeutically effective amount of a population of cells enriched for STRO-1 + multipotential cells sufficient to reduce one or more symptoms of rheumatic disease, thereby treating said rheumatic disease in said subject.
2. The method of claim 1 , wherein the rheumatic disease is selected from the group consisting of rheumatoid arthritis, Still's disease, ankylosing spondylitis, Reiter's disease, psoriatric arthritis, enteric arthritis, sacroiliitis, spondylitis and osteoarthritis.
3. The method of claim 1 , wherein the rheumatic disease is rheumatoid arthritis.
4. The method of claim 1 , wherein the subject is receiving treatment with methotrexate prior to administration of the population of cells enriched for STRO-1 + multipotential cells.
5. The method of claim 1 , wherein the STRO-1 + multipotential cells are STRO-1 bright multipotential cells.
6. The method of claim 1 , wherein the one or more symptoms are clinical features including one or more of a reduced range of motion, joint swelling or tenderness, inflammation and pain.
7. The method of claim 1 , wherein said effective amount is between 0.3×10 6 cells/kg to 2×10 6 said cells/kg.
8. The method of claim 1 , wherein the effective amount of the STRO-1 + multipotential cells is between about 1.5×10 6 to about 4×10 6 cells per kilogram.
9. The method of claim 1 , wherein the effective amount of STRO-1 + multipotential cells administered to the subject is between about 100 million to about 300 million cells.
10. The method of claim 1 , wherein the population enriched for STRO-1 + multipotential cells are administered once weekly or less often.
11. The method of claim 1 , wherein the population enriched for STRO-1 + multipotential cells are administered once every four weeks or less often.
12. The method of claim 1 , wherein the population enriched for STRO-1 + multipotential cells are autogenic or allogenic cells.
13. The method of claim 1 , wherein the population enriched for STRO-1 + multipotential cells have been culture expanded prior to administration.
14. The method of claim 1 , wherein the population enriched for STRO-1 + multipotential cells are STRO-1 bright and/or express tissue non-specific alkaline phosphatase (TNAP).
15. The method according to claim 1 , wherein the STRO-1 + multipotential cells are administered in the form of a composition comprising said STRO-1 + multipotential cells and a carrier and/or excipient.
16. The method of claim 1 , wherein evaluation criteria for reduced symptoms include a recognized disease activity score for a rheumatic disease.
17. The method of claim 1 , wherein administration is intravenous.